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In this issue, Siontis and colleagues compare an array of possible percutaneous coronary 
interventions (PCI) for treatment of in-stent restenosis.1 Most readers will recognize the hallmarks of 
a typical systematic review, with pre-defined eligibility criteria, a thorough search for studies, 
assessments of risk of bias for each study, consideration of the possibility of publication bias, and 
statistical combination (meta-analysis) of results across studies. Perhaps the most interesting aspect 
of their methodology, however, is the authors’ use of the increasingly popular technique of network 
meta-analysis. Network meta-analysis allows the authors to compare the effectiveness of each of 
eight treatments with any of the others, even when for some pairs of treatments there are no trials 
of head-to-head comparisons.  
 
Network meta-analysis methods arose through some disconnected developments during the early 
1990s,2-4 and after a dormant period were revitalized about 10 years later.5 Since then they have 
earned a critical role in comparative effectiveness research, particularly in organizations developing 
guidance and quality standards for health care, such as the National Institute for Health and Care 
Excellence (NICE) in the UK and the Canadian Agency for Drugs and Technologies in Health. The term 
‘network meta-analysis’, apparently first used in 2002,6 is inspired by a graph illustrating which 
treatments have been compared directly with each other within primary studies, as in Figure 1 of 
Siontis and colleagues.1 Network meta-analyses can be used to compare all treatments that are 
connected to each other in this network plot. The term appears to have become the generally 
preferred term over earlier competitors such as ‘multiple treatments meta-analysis’ and ‘mixed 
treatment comparisons’. 
 
At the heart of the network meta-analysis method is the notion of an ‘indirect comparison’. In the 
absence of a direct head-to-head comparison of two treatments, we must draw on results of 
separate studies involving those treatments. A naïve indirect comparison could be made by 
comparing outcomes of people receiving one treatment in one study with people receiving the other 
treatment in a different study. But this could easily give the wrong answer, since it fails to account 
for key differences between the studies and loses the advantages of randomizing patients in the first 
place: perhaps one study was longer than the other, or involved people with more severe disease. 
Instead we need to find points of reference across the two studies. This is provided by seeking 
studies that used a common comparator. Thus, for example, everolimus-eluting stents (EES) and 
balloon angioplasty (BA) have not been compared directly in a randomized trial, but both have been 
compared in separate trials with drug-coated balloons (DCB).1 The indirect comparison builds on the 
argument that if patients do better on EES than on DCB, and if they do better on DCB than on BA, 
then they ought to do better on EES than on BA. A network meta-analysis formalizes this argument 
mathematically, thus defining connections between the trials making different comparisons of 
treatments. It combines the results from all studies simultaneously, drawing on both direct 
comparisons within studies and indirect comparisons across studies via common reference 
treatments. 
 
A key strength of network meta-analysis is that it can lead to a single, coherent, ranking of the 
treatments. Among the percutaneous coronary interventions, clear winners from Siontis and 
colleagues were everolimus-eluting stents and drug-coated balloons. Across several clinical 
endpoints, these had high probabilities of being at the top of the ranking, and low probabilities of 
being low in the ranking. The authors were fortunate that the messages were clear. There was little 
between-study variation in their meta-analyses, and no evidence that the assumptions underlying 
the indirect comparisons were unreasonable. 
 
Complications and considerations in network meta-analysis have been discussed in several 
accessible texts.7-12 Differences between network meta-analysis and standard meta-analysis are not, 
in our view, as substantial as many fear. In a standard meta-analysis it is widely recognized that the 
studies need to be sufficiently similar to each other for the combined result to be meaningful. In a 
network meta-analysis, they need to be sufficiently similar in ways other than the particular choice 
of treatments being compared. This will not always be the case, but requires the same type of 
reasoning that ought to be used when making the decision to combine across studies in a standard 
meta-analysis.  
 
Although there are additional technical challenges in network meta-analysis from a statistical 
perspective, which we won’t go into here, there are also interesting opportunities to interrogate the 
evidence in new ways. For instance, if both a direct comparison and an indirect comparison is 
available for a pair of treatments, then we can examine whether they agree with each other. For 
example, Siontis and colleagues identified trials of each of DCB and BA against paclitax-eleluting 
stents (PES).1 Fortunately, the indirect comparison of DCB vs BA through the common comparator of 
PES did not conflict with the direct head-to-head trials of DCB vs BA. Furthermore, there was a three-
arm trial of all three of these treatments that added further justification to the joint synthesis. 
Examinations like this are known as investigations of ‘incoherence’ or ‘inconsistency’ and will often 
be found in a report of a network meta-analysis. If incoherence is identified it may be due to various 
factors, including non-comparability of the studies or different biases affecting different 
comparisons.7 Strategies for addressing incoherence include (i) narrowing the criteria for including 
studies in the analysis, (ii) exploring possible causes using meta-regression, and (iii) refraining from 
synthesizing the data. 
 
One of the challenges in network meta-analyses is how to convey the complex set of outputs from 
the analysis. Results are available for all pair-wise comparisons of treatments in the network. With 
five treatments this produces 10 pairs; for 10 treatments we have 45 pairs; and for 20 treatments we 
have 190 pairs. With relatively small numbers of treatments, we can illustrate all pair-wise 
comparisons in matrices such as those Siontis and colleagues use for their eight treatments. For 
larger problems some reduction may be needed, such as restriction to the treatments of primary 
interest or grouping of similar treatments; there is undoubtedly room for development of novel 
presentational approaches. Caution is often required when networks appear to be large (in terms of 
number of treatments) but contain sparse data (just one or two studies for each available direct 
comparison). 
 
It is not surprising that network meta-analyses have become so popular, given that they answer the 
real questions of interest to decision makers, who are usually faced with an array of treatment 
options and not just two. They are the natural evolution of meta-analysis, and they rest on 
fundamentally the same considerations as all other meta-analyses. We anticipate that they will 
become the new ‘norm’ for combining results of multiple clinical trials. They are not without 
challenges, but then neither are any other approaches to combining evidence across studies that 
were not designed with their statistical synthesis in mind. And unlike standard meta-analyses, 
network meta-analyses offer a valuable opportunity to examine whether a body of evidence is 
coherent, by ‘triangulating’ across trials making different comparisons of treatments for the same 
condition. 
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